Martin Shkreli

An activist investor has announced building a significant, active position in Quantum Computing Inc. (QCLS), signaling a strong vote of confidence in the company's future. This presents an opportunity for investors to gain exposure to the high-growth quantum computing sector alongside influential involvement. A separate, high-risk opportunity exists with Capricor Therapeutics (CAPR), a biotech company with a major upcoming catalyst. The stock's value is tied to the FDA's decision on its Duchenne muscular dystrophy drug, Deremyocel, following the company's recent submission of positive trial data. A final FDA decision is targeted for around July of next year, creating a significant binary event for investors.